Risks in managing use-by dates for products handled
First written in FY2022. 1 of 3 entries say "Mitigated", first in FY2023. Latest entry: FY2024-Q1.
1 other company's latest entry also says "Restated".
- FY2024-Q1RestatedAnnual report
「During the first quarter of the current fiscal year, there were no new occurrences of the major risks that management recognises could materially affect the financial position, operating results or cash flows of the Group among the matters relating to business conditions, financial conditions and other matters described in the quarterly report, and no material changes to the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
The company explained that there have been no significant changes regarding the risk of inadequate expiry-date management for products handled. - FY2023MitigatedAnnual report
「To avoid such incidents, the group is working to improve and strengthen its expiry-date management system through regular physical inventory counts and the thorough implementation and verification of other operating procedures.」
As measures addressing the risk of inadequate expiry-date management, the company specifically described regular physical inventory counts and the thorough implementation and verification of operating procedures. - FY2022First statedAnnual report
「If products that have passed their expiry dates were distributed due to human error or a problem within the group, causing serious health damage, sales activities could be affected through the revocation of licenses and other authorizations related to the sale of medical devices and other products or a decline in confidence in the group. Significant costs could also arise from compensation to patients and medical institutions and from improving and strengthening the expiry-date management system, potentially affecting the group's sales and earnings.」
The company has identified as a new risk the health damage, licensing and authorization issues, reputational impact and compensation costs that could result from distributing medical devices, pharmaceuticals and other products after their expiry dates.